{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:25:10Z","timestamp":1786451110743,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With a rapidly aging population, adequate blood pressure (BP) control is critical for hypertension management and prevention of cardiovascular events. Impressive cardiovascular benefits have been observed with intensive BP control (SBP target, &lt;120\u2009mmHg) in the SPRINT (Systolic Blood Pressure Intervention Trial) study, even in patients 75 years of age or older. A most recent meta-analysis including 51 randomized trials with over 350,000 participants from the BPLTTC (The Blood Pressure Lowering\u00a0Treatment Trialists\u2019 Collaboration) showed that BP lowering is effective in older people for reducing major cardiovascular events. The STEP (Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients) study\u2014a multicenter, randomized, controlled trial conducted in China, provided important evidence that intensive BP treatment (SBP target, 110\u2009mmHg to &lt;130\u2009mmHg) benefits older hypertensive patients (aged 60\u201380 years) and reduced the incidence of cardiovascular events than standard treatment (target 130\u2009mmHg to &lt;150\u2009mmHg). Because Asian people have a higher burden of hypertension and stroke than Caucasian people, intensive BP treatment has more advantages in reducing the risk of cardiovascular events including stroke in Asian hypertensive patients than in Caucasian people. Home BP monitoring is helpful to facilitate hypertension management for older patients. It should also be noted that clinical decision-making should be on a patient basis, such as fragility, diabetes, stroke, and other comorbidities, with tailored BP targets. Here we review the important clinical trials of BP control in elderly hypertension, interpretate the main findings of STEP, and also discuss the perspectives of managing hypertension in Asia.<\/jats:p>","DOI":"10.1038\/s41440-022-00875-7","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T14:02:58Z","timestamp":1647007378000},"page":"576-582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["STEP to blood pressure management of elderly hypertension: evidence from Asia"],"prefix":"10.1038","volume":"45","author":[{"given":"Wei-li","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"875_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(16)31919-5","volume":"389","author":"NCD Risk Factor Collaboration.","year":"2017","unstructured":"NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measure studies with 19.1 million participants. Lancet. 2017;389:37\u201355.","journal-title":"Lancet."},{"key":"875_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamainternmed.2016.0190","volume":"176","author":"S Lewington","year":"2016","unstructured":"Lewington S, Lacey B, Clarke R, Guo Y, Kong XL, Yang L, et al. The Burden of Hypertension and Associated Risk for Cardiovascular Mortality in China. JAMA Intern Med. 2016;176:524\u201332.","journal-title":"JAMA Intern Med."},{"key":"875_CR3","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/S0140-6736(17)32478-9","volume":"390","author":"J Lu","year":"2017","unstructured":"Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017;390:2549\u201358.","journal-title":"Lancet."},{"key":"875_CR4","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.117.032380","volume":"137","author":"Z Wang","year":"2018","unstructured":"Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, et al. Status of Hypertension in China: Results from the China Hypertension Survey, 2012-2015. Circulation. 2018;137:2344\u201356.","journal-title":"Circulation."},{"key":"875_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441\u201350.","journal-title":"Circulation."},{"key":"875_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/hr.2014.169","volume":"38","author":"JB Park","year":"2015","unstructured":"Park JB, Kario K, Wang JG. Systolic hypertension: an increasing clinical challenge in Asia. Hypertens Res. 2015;38:227\u201336.","journal-title":"Hypertens Res."},{"key":"875_CR7","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","volume":"384","author":"The SPRINT Research Group.","year":"2021","unstructured":"The SPRINT Research Group. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med. 2021;384:1921\u201330.","journal-title":"N Engl J Med"},{"key":"875_CR8","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1001\/jama.2016.7050","volume":"315","author":"JD Williamson","year":"2016","unstructured":"Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged \u226575 years: a randomized clinical trial. JAMA. 2016;315:2673\u201382.","journal-title":"JAMA."},{"key":"875_CR9","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","volume":"398","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration.","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet. 2021;398:1053\u201364.","journal-title":"Lancet."},{"key":"875_CR10","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268\u201379. STEP Study Group","journal-title":"N Engl J Med."},{"key":"875_CR11","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1097\/00004872-199816120-00016","volume":"16","author":"L Liu","year":"1998","unstructured":"Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens. 1998;16:1823\u20139.","journal-title":"J Hypertens."},{"key":"875_CR12","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1097\/01.hjh.0000194120.42722.ac","volume":"23","author":"L Liu","year":"2005","unstructured":"Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A, et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157\u201372.","journal-title":"J Hypertens."},{"key":"875_CR13","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr039","volume":"32","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Zhang X, Liu L, Zanchetti A, FEVER Study G. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J. 2011;32:1500\u20138.","journal-title":"Eur Heart J."},{"key":"875_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1161\/HYPERTENSIONAHA.109.146035","volume":"56","author":"T Ogihara","year":"2010","unstructured":"Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension. 2010;56:196\u2013202.","journal-title":"Hypertension."},{"key":"875_CR15","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1291\/hypres.31.2115","volume":"31","author":"Group JS.","year":"2008","unstructured":"Group JS. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31:2115\u201327.","journal-title":"Hypertens Res."},{"key":"875_CR16","doi-asserted-by":"crossref","unstructured":"ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC, Jr., Grimm RH, Jr., Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575\u201385.","DOI":"10.1056\/NEJMoa1001286"},{"key":"875_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/HYPERTENSIONAHA.118.11408","volume":"72","author":"T Tsujimoto","year":"2018","unstructured":"Tsujimoto T, Kajio H. Benefits of intensive blood pressure treatment in patients with type 2 diabetes mellitus receiving standard but not intensive glycemic control. Hypertension. 2018;72:323\u201330.","journal-title":"Hypertension."},{"key":"875_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(13)60852-1","volume":"382","author":"OR Benavente","year":"2013","unstructured":"SPS3 Study Group, Benavente OR, Coffey CS, Conwit R, Hart RG, cClure LA, Pearce LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507\u201315.","journal-title":"Lancet."},{"key":"875_CR19","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/jamainternmed.2020.5028","volume":"180","author":"PE Drawz","year":"2020","unstructured":"Drawz PE, Agarwal A, Dwyer JP, Horwitz E, Lash J, Lenoir K, et al. Concordance between blood pressure in the systolic blood pressure intervention trial and in routine clinical practice. JAMA Intern Med. 2020;180:1655\u201363.","journal-title":"JAMA Intern Med."},{"key":"875_CR20","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/ene.13411","volume":"24","author":"JH Park","year":"2017","unstructured":"Park JH, Ovbiagele B. Post-stroke diastolic blood pressure and risk of recurrent vascular events. Eur J Neurol. 2017;24:1416\u201323.","journal-title":"Eur J Neurol"},{"key":"875_CR21","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.jacc.2016.07.754","volume":"68","author":"JW McEvoy","year":"2016","unstructured":"McEvoy JW, Chen Y, Rawlings A, Hoogeveen RC, Ballantyne CM, Blumenthal RS, et al. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. J Am Coll Cardiol. 2016;68:1713\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"875_CR22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jama.2018.21442","volume":"321","author":"JD Williamson","year":"2019","unstructured":"SPRINT MIND Investigators for the SPRINT Research G., Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321:553\u201361.","journal-title":"JAMA."},{"key":"875_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jama.2019.10551","volume":"322","author":"IM Nasrallah","year":"2019","unstructured":"SPRINT MIND Investigators for the SPRINT Research G., Nasrallah IM, Pajewski NM, Auchus AP, Chelune G, Cheung AK, et al. Association of intensive vs standard blood pressure control with cerebral white matter lesions. JAMA. 2019;322:524\u201334.","journal-title":"JAMA."},{"key":"875_CR24","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1097\/HJH.0b013e3283018333","volume":"26","author":"M Nagai","year":"2008","unstructured":"Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. J Hypertens. 2008;26:1636\u201341.","journal-title":"J Hypertens"},{"key":"875_CR25","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"2018","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;2018:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"875_CR26","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/ AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127\u2013248.","journal-title":"J Am Coll Cardiol."},{"key":"875_CR27","first-page":"182","volume":"16","author":"Joint Committee for Guideline Revision.","year":"2019","unstructured":"Joint Committee for Guideline Revision. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol. 2019;16:182\u2013241.","journal-title":"J Geriatr Cardiol."},{"key":"875_CR28","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res."},{"key":"875_CR29","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/jch.13763","volume":"22","author":"S Hoshide","year":"2020","unstructured":"Hoshide S, Kario K, Tomitani N, Kabutoya T, Chia YC, Park S, et al. Highlights of the 2019 Japanese Society of Hypertension Guidelines and perspectives on the management of Asian hypertensive patients. J Clin Hypertens. 2020;22:369\u201377.","journal-title":"J Clin Hypertens"},{"key":"875_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40885-019-0124-x","volume":"25","author":"HY Lee","year":"2019","unstructured":"Lee HY, Shin J, Kim GH, Park S, Ihm SH, Kim HC, et al. 2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens. 2019;25:20.","journal-title":"Clin Hypertens."},{"key":"875_CR31","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamacardio.2016.3517","volume":"1","author":"IB Richman","year":"2016","unstructured":"Richman IB, Fairley M, J\u00f8rgensen ME, Schuler A, Owens DK, Goldhaber-Fiebert JD. Cost-effectiveness of intensive blood pressure management. JAMA Cardiol. 2016;1:872\u20139.","journal-title":"JAMA Cardiol."},{"key":"875_CR32","doi-asserted-by":"publisher","first-page":"e1003515","DOI":"10.1371\/journal.pmed.1003515","volume":"18","author":"C Li","year":"2021","unstructured":"Li C, Chen K, Cornelius V, Tomeny E, Wang Y, Yang X, et al. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: a cost-effectiveness modeling study. PLoS Med. 2021;18:e1003515.","journal-title":"PLoS Med"},{"key":"875_CR33","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1161\/CIRCULATIONAHA.108.790048","volume":"118","author":"H Ueshima","year":"2008","unstructured":"Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation. 2008;118:2702\u20139.","journal-title":"Circulation."},{"key":"875_CR34","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMe2112992","volume":"385","author":"MR Nelson","year":"2021","unstructured":"Nelson MR. Moving the goalposts for blood pressure\u2014time to act. N Engl J Med. 2021;385:1328\u20139.","journal-title":"N Engl J Med."}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00875-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00875-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00875-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T03:06:37Z","timestamp":1647399997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00875-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["875"],"URL":"https:\/\/doi.org\/10.1038\/s41440-022-00875-7","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]},"assertion":[{"value":"18 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}